Samsung to Invest $90 Billion in South Korea to Expand AI Chip, Display, and Battery Production 
Asian Stocks Rebound as Tech Shares Rally on Fed Rate Cut Hopes and Easing Iran Tensions 
TetherMax Rebranding Highlights Official Exchange Partnerships as Foundation of Trust 
Moody’s Says Peru’s President-Elect Keiko Fujimori Could Boost Investor Confidence 
Gold Price Holds Above $4,000 as Fed Rate Hike Expectations and U.S. Jobs Data Weigh on Market 
Asian Stocks Slide as Chip Shares Tumble Ahead of Key U.S. Jobs Report 
Gold Price Surges Above $4,120 as Weak US Jobs Data Lowers Fed Rate Hike Expectations 
Anthropic Restores Claude Fable 5 and Mythos 5 After U.S. Lifts AI Export Controls 
Switch Seeks $2 Billion Funding at Nearly $50 Billion Valuation Ahead of Potential IPO 
Oil Prices Steady as U.S.-Iran Talks Ease Supply Fears Ahead of Holiday Weekend 
Wall Street Ends Mixed as Weak Jobs Data Lowers Fed Rate Hike Bets, Chip Stocks Tumble 
Denmark Central Bank Intervenes to Support Krone Peg Against Euro 
Sodexo Raises 2026 Revenue Outlook After Strong Q3 Sales Beat 
Australia Trade Balance Swings to Surprise Deficit as Imports Outpace Exports in May 
Northern Star Appoints New CEO as Activist Elliott Pushes for Leadership Overhaul 
Japan Signals Surprise Yen Intervention Strategy as BOJ Hawkish Stance Puts FX Traders on Alert 
Trump Administration to Launch Voluntary AI Standards for Frontier Models 
KT Corp. has collaborated with US-based NeuroSigma Inc. to build a business model and technology for electronic medicine to treat neurological disorders, such as attention deficit hyperactivity disorder (ADHD), depression, and epilepsy.
Under the partnership, KTS will support the development of the next version of NeuroSigma's external trigeminal nerve stimulation (eTNS®) system while producing and commercializing the device in South Korea.
NeuoSigma is credited for developing the first device cleared by the US Food and Drug Administration to treat pediatric ADHD--the Monarch external Trigeminal Nerve Stimulation system,
The telecom operator said NeuoSigma's pediatric ADHD electronic treatment has fewer side effects than other existing medication and is set to receive further clearance from the FDA on depression and epilepsy treatment using the technology.
